{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:37:50Z","timestamp":1792726670739,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significant advances in early detection and therapeutic strategies, breast cancer (BC) continues to pose a major public health challenge.<\/jats:p>\n                    <jats:p>The treatment of HER2-positive (HER2\u2009+) BC has evolved substantially over recent years with the advent of monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody\u2013drug conjugates (ADCs). Clinical progress has been significantly accelerated by a deeper understanding of the immune-regulatory properties of this subtype and its interactions with the tumor microenvironment.<\/jats:p>\n                    <jats:p>Despite the availability of effective HER2-targeted therapies, approximately one-third of patients develops resistance, highlighting the need for novel and more durable treatment strategies. Indeed, while current treatments have shown promising efficacy by promoting a \u201cpassive immune response,\u201d they are associated with the emergence of resistant clones.<\/jats:p>\n                    <jats:p>Conversely, vaccine-based therapies are designed to elicit a durable \u201cactive immune response\u201d by presenting tumor-associated antigens that stimulate the host immune system to recognize and eliminate malignant cells. This approach has the potential to generate long-lasting immunological memory, preventing recurrence, disease progression, and the emergence of immune-evasive tumor variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This review provides a comprehensive overview of cancer vaccines strategies for HER2\u2009+\u2009BC with emphasis on their mechanisms, advantages, limitations, and their current developmental status. We explore diverse delivery platforms, including peptide\/protein-based, nucleic acid, and cell-based vaccines. The clinical utility of these strategies is assessed across different disease settings: from prevention and interception in pre-invasive lesions, to the (neo)adjuvant treatment of early-stage BC and the management of advanced metastatic disease. While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses. Furthermore, we discuss emerging innovations such as neoantigen discovery, next-generation adjuvants (e.g., TLR and STING agonists), and novel combinatorial approaches with checkpoint inhibitors to overcome immune evasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although most BC vaccines remain under clinical investigation, they represent a promising frontier for achieving disease control and the coming decade is expected to yield pivotal insights into their clinical utility and therapeutic potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03789-1","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:54:24Z","timestamp":1784987664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling the use of vaccine therapy in HER2-positive breast cancer: a comprehensive review of current state and future perspectives"],"prefix":"10.1186","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"Aldo","family":"Caltavituro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2417-0589","authenticated-orcid":false,"given":"Claudia","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-4705","authenticated-orcid":false,"given":"Michela","family":"Palleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5550-3019","authenticated-orcid":false,"given":"Miriam","family":"Pirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Cantile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"3789_CR1","doi-asserted-by":"publisher","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases \u2014 elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16\u201325. https:\/\/doi.org\/10.1016\/j.coi.2014.01.004.","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"3789_CR2","doi-asserted-by":"publisher","unstructured":"Khalaf K, Hana D, Chou JTT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front Immunol. 2021;12:656364. https:\/\/doi.org\/10.3389\/fimmu.2021.656364.","DOI":"10.3389\/fimmu.2021.656364"},{"key":"3789_CR3","doi-asserted-by":"publisher","unstructured":"Lu Y, et al. Evaluating the immunologically \u201ccold\u201d tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Breast Cancer Res. 2024;26(1):104. https:\/\/doi.org\/10.1186\/s13058-024-01844-3.","DOI":"10.1186\/s13058-024-01844-3"},{"key":"3789_CR4","doi-asserted-by":"publisher","unstructured":"Adams S, et al. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019;5(8):205. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7147.","DOI":"10.1001\/jamaoncol.2018.7147"},{"key":"3789_CR5","doi-asserted-by":"publisher","unstructured":"Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u2013218. https:\/\/doi.org\/10.1038\/nature12213.","DOI":"10.1038\/nature12213"},{"key":"3789_CR6","doi-asserted-by":"publisher","unstructured":"Savas P, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u2013241. https:\/\/doi.org\/10.1038\/nrclinonc.2015.215.","DOI":"10.1038\/nrclinonc.2015.215"},{"key":"3789_CR7","doi-asserted-by":"publisher","unstructured":". Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020;6(1):10. https:\/\/doi.org\/10.1038\/s41523-020-0153-3.","DOI":"10.1038\/s41523-020-0153-3"},{"key":"3789_CR8","doi-asserted-by":"publisher","unstructured":"Loi S, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial. Lancet Oncol. 2019;20(3):371\u2013382. https:\/\/doi.org\/10.1016\/S1470-2045(18)30812-X.","DOI":"10.1016\/S1470-2045(18)30812-X"},{"key":"3789_CR9","doi-asserted-by":"publisher","unstructured":"Emens LA, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283\u20131295. https:\/\/doi.org\/10.1016\/S1470-2045(20)30465-4.","DOI":"10.1016\/S1470-2045(20)30465-4"},{"key":"3789_CR10","doi-asserted-by":"publisher","unstructured":"Dirix LY, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671\u2013686. https:\/\/doi.org\/10.1007\/s10549-017-4537-5.","DOI":"10.1007\/s10549-017-4537-5"},{"key":"3789_CR11","doi-asserted-by":"publisher","unstructured":"Huober J, et al. Atezolizumab With Neoadjuvant Anti\u2013Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2\u2013Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. JCO. 2022;40(25):2946\u20132956. https:\/\/doi.org\/10.1200\/JCO.21.02772.","DOI":"10.1200\/JCO.21.02772"},{"key":"3789_CR12","doi-asserted-by":"publisher","unstructured":"Caltavituro A, et al. Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions. Crit Rev Oncol Hematol. 2025;206:104577. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104577.","DOI":"10.1016\/j.critrevonc.2024.104577"},{"key":"3789_CR13","doi-asserted-by":"publisher","unstructured":"Buono G, et al. CAR-T cell therapy for breast cancer: Current status and future perspective. Cancer Treat Rev. 2025;133:102868. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102868.","DOI":"10.1016\/j.ctrv.2024.102868"},{"key":"3789_CR14","doi-asserted-by":"publisher","unstructured":"Pallerla S, Abdul AURM, Comeau J, Jois S. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. IJMS. 2021;22(2):779. https:\/\/doi.org\/10.3390\/ijms22020779.","DOI":"10.3390\/ijms22020779"},{"key":"3789_CR15","doi-asserted-by":"publisher","unstructured":"Van Der Burg SH. Correlates of immune and clinical activity of novel cancer vaccines. Seminars in Immunology. 2018;39:119\u2013136. https:\/\/doi.org\/10.1016\/j.smim.2018.04.001.","DOI":"10.1016\/j.smim.2018.04.001"},{"key":"3789_CR16","doi-asserted-by":"publisher","unstructured":"Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: Has the time finally come? Eur J Cancer. 2022;160:150\u2013174. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.027.","DOI":"10.1016\/j.ejca.2021.10.027"},{"key":"3789_CR17","doi-asserted-by":"publisher","unstructured":"Disis ML, Cecil DL. Breast cancer vaccines for treatment and prevention. Breast Cancer Res Treat. 2022;191(3):481\u2013489. https:\/\/doi.org\/10.1007\/s10549-021-06459-2.","DOI":"10.1007\/s10549-021-06459-2"},{"key":"3789_CR18","doi-asserted-by":"publisher","unstructured":"Zachariah NN, et al. Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. Front Immunol. 2021;12:786286. https:\/\/doi.org\/10.3389\/fimmu.2021.786286.","DOI":"10.3389\/fimmu.2021.786286"},{"key":"3789_CR19","doi-asserted-by":"publisher","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991.","DOI":"10.1038\/ni1102-991"},{"key":"3789_CR20","doi-asserted-by":"publisher","unstructured":"Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135\u2013146. https:\/\/doi.org\/10.1038\/nrc3670.","DOI":"10.1038\/nrc3670"},{"key":"3789_CR21","doi-asserted-by":"publisher","unstructured":"Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2023;45(2):253\u2013264. https:\/\/doi.org\/10.1007\/s00281-022-00966-0.","DOI":"10.1007\/s00281-022-00966-0"},{"key":"3789_CR22","doi-asserted-by":"publisher","unstructured":"Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase. Cancer Res. 2005;65(2)650\u2013656. https:\/\/doi.org\/10.1158\/0008-5472.650.65.2.","DOI":"10.1158\/0008-5472.650.65.2"},{"key":"3789_CR23","doi-asserted-by":"publisher","unstructured":"Mei P, Freitag CE, Wei L, Zhang Y, Parwani AV, Li Z. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagn Pathol. 2020;15(1):50. https:\/\/doi.org\/10.1186\/s13000-020-00971-7.","DOI":"10.1186\/s13000-020-00971-7"},{"key":"3789_CR24","doi-asserted-by":"publisher","unstructured":"Keenan BP, Jaffee EM. Whole Cell Vaccines\u2014Past Progress and Future Strategies. Seminars in Oncology. 2012;39(3):276\u2013286. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.02.007.","DOI":"10.1053\/j.seminoncol.2012.02.007"},{"key":"3789_CR25","doi-asserted-by":"publisher","unstructured":"Yan HX, et al. Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2. Oncol Rep. 2013;29(4):1510\u20131516. https:\/\/doi.org\/10.3892\/or.2013.2282.","DOI":"10.3892\/or.2013.2282"},{"key":"3789_CR26","doi-asserted-by":"publisher","unstructured":"Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995;181(6):2109\u20132117. https:\/\/doi.org\/10.1084\/jem.181.6.2109.","DOI":"10.1084\/jem.181.6.2109"},{"key":"3789_CR27","doi-asserted-by":"publisher","unstructured":"Zhang L, Huang Y, Lindstrom AR, Lin TY, Lam KS, Li Y. Peptide-based materials for cancer immunotherapy. Theranostics. 2019;9(25):7807\u20137825. https:\/\/doi.org\/10.7150\/thno.37194.","DOI":"10.7150\/thno.37194"},{"key":"3789_CR28","doi-asserted-by":"publisher","unstructured":"Malonis RJ, Lai JR, Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev. 2020;120(6):3210\u20133229. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00472.","DOI":"10.1021\/acs.chemrev.9b00472"},{"key":"3789_CR29","doi-asserted-by":"publisher","unstructured":"Kawashima I, et al. The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors. Hum Immunol. 1998;59(1):1\u201314. https:\/\/doi.org\/10.1016\/S0198-8859(97)00255-3.","DOI":"10.1016\/S0198-8859(97)00255-3"},{"key":"3789_CR30","doi-asserted-by":"publisher","unstructured":"Ura T, Okuda K, Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines. 2014;2(3):624\u2013641. https:\/\/doi.org\/10.3390\/vaccines2030624.","DOI":"10.3390\/vaccines2030624"},{"key":"3789_CR31","doi-asserted-by":"publisher","unstructured":"Melo\u00a0ARDS, et al.\u00a0Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency. Genes. 2022;13(12):2287.\u00a0https:\/\/doi.org\/10.3390\/genes13122287.","DOI":"10.3390\/genes13122287"},{"key":"3789_CR32","doi-asserted-by":"publisher","unstructured":"Watt WC, Cecil DL, Disis ML Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer. Semin Immunopathol. 2017;39(3):245\u2013253.\u00a0https:\/\/doi.org\/10.1007\/s00281-016-0596-7.","DOI":"10.1007\/s00281-016-0596-7"},{"key":"3789_CR33","doi-asserted-by":"publisher","unstructured":"Sharma\u00a0A, et al.\u00a0HER\u20102 pulsed dendritic cell vaccine can eliminate HER\u20102 expression and impact ductal carcinoma in situ. Cancer. 2012;118(17):4354\u20134362.\u00a0https:\/\/doi.org\/10.1002\/cncr.26734.","DOI":"10.1002\/cncr.26734"},{"key":"3789_CR34","doi-asserted-by":"publisher","unstructured":"Yan Y, Yao D, Li X. Immunological Mechanism and Clinical Application of PAMP Adjuvants. PRA. 2021;16(1):30\u201343.\u00a0https:\/\/doi.org\/10.2174\/1574892816666210201114712.","DOI":"10.2174\/1574892816666210201114712"},{"key":"3789_CR35","doi-asserted-by":"publisher","unstructured":"Zhu\u00a0J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557\u20131569.\u00a0https:\/\/doi.org\/10.1182\/blood-2008-05-078154.","DOI":"10.1182\/blood-2008-05-078154"},{"key":"3789_CR36","doi-asserted-by":"publisher","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol.\u00a0201;28(1):445\u2013489.\u00a0https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101212.","DOI":"10.1146\/annurev-immunol-030409-101212"},{"key":"3789_CR37","doi-asserted-by":"publisher","unstructured":"Chen\u00a0W, Konkel JE. TGF- and \u201cAdaptive\u201d Foxp3+ Regulatory T cells. J Mol Cell Biol. 2010;2(1):30\u201336.\u00a0https:\/\/doi.org\/10.1093\/jmcb\/mjp004.","DOI":"10.1093\/jmcb\/mjp004"},{"key":"3789_CR38","doi-asserted-by":"publisher","unstructured":"Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The Role of IL-10 and TGF-\u03b2 in the Differentiation and Effector Function of T Regulatory Cells. Int Arch Allergy Immunol. 2002;129(4):263\u2013276.\u00a0https:\/\/doi.org\/10.1159\/000067596.","DOI":"10.1159\/000067596"},{"key":"3789_CR39","doi-asserted-by":"publisher","unstructured":"Chaudhry\u00a0A, et al.\u00a0Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation. Immunity. 2011;34(4):566\u2013578.\u00a0https:\/\/doi.org\/10.1016\/j.immuni.2011.03.018.","DOI":"10.1016\/j.immuni.2011.03.018"},{"key":"3789_CR40","doi-asserted-by":"publisher","unstructured":"Dong C. Differentiation and function of pro-inflammatory Th17 cells.\u00a0Microbes Infect. 2009;11(5):584\u2013588.\u00a0https:\/\/doi.org\/10.1016\/j.micinf.2009.04.001.","DOI":"10.1016\/j.micinf.2009.04.001"},{"key":"3789_CR41","doi-asserted-by":"publisher","unstructured":"Kimura A, Kishimoto T. IL\u20106: Regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40(7):1830\u20131835.\u00a0https:\/\/doi.org\/10.1002\/eji.201040391.","DOI":"10.1002\/eji.201040391"},{"key":"3789_CR42","doi-asserted-by":"publisher","unstructured":"Wang J, Zhao X, Wan YY. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002\u20131022.\u00a0https:\/\/doi.org\/10.1038\/s41423-023-01036-7.","DOI":"10.1038\/s41423-023-01036-7"},{"key":"3789_CR43","doi-asserted-by":"publisher","unstructured":"Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14\u201324.\u00a0https:\/\/doi.org\/10.1016\/j.cyto.2015.05.010.","DOI":"10.1016\/j.cyto.2015.05.010"},{"key":"3789_CR44","doi-asserted-by":"publisher","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. Immunity. 2013;38(1):13\u201325.\u00a0https:\/\/doi.org\/10.1016\/j.immuni.2013.01.004.","DOI":"10.1016\/j.immuni.2013.01.004"},{"key":"3789_CR45","doi-asserted-by":"publisher","unstructured":"Cote-Sierra\u00a0J, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A.\u00a02004;101(11):3880\u20133885.\u00a0https:\/\/doi.org\/10.1073\/pnas.0400339101.","DOI":"10.1073\/pnas.0400339101"},{"key":"3789_CR46","doi-asserted-by":"publisher","unstructured":"Manetti\u00a0R, et al.\u00a0Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177(4):1199\u20131204.\u00a0https:\/\/doi.org\/10.1084\/jem.177.4.1199.","DOI":"10.1084\/jem.177.4.1199"},{"key":"3789_CR47","doi-asserted-by":"publisher","unstructured":"Harada\u00a0S, et al.\u00a0The significance of HER\u20102\/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol. 2011;104(5):458\u2013465.\u00a0https:\/\/doi.org\/10.1002\/jso.21973.","DOI":"10.1002\/jso.21973"},{"key":"3789_CR48","doi-asserted-by":"publisher","unstructured":"Han\u00a0K, et al.\u00a0Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence. Clin Oncol. 2012;24(3):183\u2013189.\u00a0https:\/\/doi.org\/10.1016\/j.clon.2011.09.008.","DOI":"10.1016\/j.clon.2011.09.008"},{"key":"3789_CR49","doi-asserted-by":"publisher","unstructured":"Czerniecki BJ, Roses RE, Koski GK. Development of Vaccines for High-Risk Ductal Carcinoma In situ of the Breast. Cancer Res.\u00a02007;67(14):6531\u20136534.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0878.","DOI":"10.1158\/0008-5472.CAN-07-0878"},{"key":"3789_CR50","doi-asserted-by":"publisher","unstructured":"Miligy\u00a0IM, et al.\u00a0The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer. 2019;120(11):1075\u20131082.\u00a0https:\/\/doi.org\/10.1038\/s41416-019-0436-3.","DOI":"10.1038\/s41416-019-0436-3"},{"key":"3789_CR51","doi-asserted-by":"publisher","unstructured":"Gil Del Alcazar CR, Ale\u010dkovi\u0107 M, Polyak K. Immune Escape during Breast Tumor Progression. Cancer Immunol Res.\u00a02020;8(4):422\u2013427.\u00a0https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0786.","DOI":"10.1158\/2326-6066.CIR-19-0786"},{"key":"3789_CR52","doi-asserted-by":"publisher","unstructured":"Czerniecki\u00a0BJ, et al.\u00a0Targeting HER-2\/ neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Res. 2007;67(4):1842\u20131852.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4038.","DOI":"10.1158\/0008-5472.CAN-06-4038"},{"key":"3789_CR53","doi-asserted-by":"publisher","unstructured":"Palucka\u00a0K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265\u2013277.\u00a0https:\/\/doi.org\/10.1038\/nrc3258.","DOI":"10.1038\/nrc3258"},{"key":"3789_CR54","doi-asserted-by":"publisher","unstructured":"Lowenfeld L, et al.\u00a0Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial. Clin Cancer Res. 2017;23(12):2961\u20132971.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1924.","DOI":"10.1158\/1078-0432.CCR-16-1924"},{"key":"3789_CR55","doi-asserted-by":"publisher","unstructured":"Mittendorf\u00a0EA, et al.\u00a0Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clin Cancer Res. 2019;25(14):4248\u20134254.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2867.","DOI":"10.1158\/1078-0432.CCR-18-2867"},{"key":"3789_CR56","doi-asserted-by":"publisher","unstructured":"Gall\u00a0VA, et al.\u00a0Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017;77(19):5374\u20135383.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2774.","DOI":"10.1158\/0008-5472.CAN-16-2774"},{"key":"3789_CR57","doi-asserted-by":"publisher","unstructured":"Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care. 2016;11(2):116\u2013121.\u00a0https:\/\/doi.org\/10.1159\/000446097.","DOI":"10.1159\/000446097"},{"key":"3789_CR58","doi-asserted-by":"publisher","unstructured":"O\u2019Shea\u00a0AE, et al.\u00a0Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.\u00a0Cancer Prevent Res. 2023;16(6):333\u2013341.\u00a0https:\/\/doi.org\/10.1158\/1940-6207.CAPR-22-0388.","DOI":"10.1158\/1940-6207.CAPR-22-0388"},{"key":"3789_CR59","doi-asserted-by":"publisher","unstructured":"Schlam I, Loi S, Salgado R, Swain SM. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. ESMO Open. 2025;10(2):104120.\u00a0https:\/\/doi.org\/10.1016\/j.esmoop.2024.104120.","DOI":"10.1016\/j.esmoop.2024.104120"},{"key":"3789_CR60","doi-asserted-by":"publisher","unstructured":"Loibl\u00a0S, et al.\u00a0Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149\u20131158.\u00a0https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940.","DOI":"10.1016\/j.annonc.2022.07.1940"},{"key":"3789_CR61","doi-asserted-by":"publisher","unstructured":"Schmid\u00a0P, et al.\u00a0Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810\u2013821.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1910549.","DOI":"10.1056\/NEJMoa1910549"},{"key":"3789_CR62","doi-asserted-by":"publisher","unstructured":"Debien\u00a0V, et al.\u00a0Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7.\u00a0https:\/\/doi.org\/10.1038\/s41523-023-00508-3.","DOI":"10.1038\/s41523-023-00508-3"},{"key":"3789_CR63","doi-asserted-by":"publisher","unstructured":"Soyano\u00a0A, et al.\u00a0Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer. J Immunother Cancer. 2026;14(1):e013590.\u00a0https:\/\/doi.org\/10.1136\/jitc-2025-013590.","DOI":"10.1136\/jitc-2025-013590"},{"key":"3789_CR64","doi-asserted-by":"publisher","unstructured":"Clifton\u00a0GT, et al.\u00a0Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clin Cancer Res. 2020;26(11):2515\u20132523.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2741.","DOI":"10.1158\/1078-0432.CCR-19-2741"},{"key":"3789_CR65","doi-asserted-by":"publisher","unstructured":"Tiwari\u00a0A, et al.\u00a0Abstract P4\u201307\u201323: Results of a Phase 2 Trial of Combination Immunotherapy with Concurrent Nelipepimut-S + GM-CSF and Trastuzumab in High-risk HER2+ Breast Cancer Patients. Cancer Res. 2023;83(5_Supplement):P4\u201307\u201323-P4\u201307\u201323.\u00a0https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-P4-07-23.","DOI":"10.1158\/1538-7445.SABCS22-P4-07-23"},{"key":"3789_CR66","doi-asserted-by":"publisher","unstructured":"Patel SS, McWilliams DB, Patel MS, Fischette CT, Thompson J, Daugherty FJ. Abstract PS10\u201323: Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2\/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. Cancer Res. 2021;81(4_Supplement):PS10\u201323-PS10\u201323.\u00a0https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PS10-23.","DOI":"10.1158\/1538-7445.SABCS20-PS10-23"},{"key":"3789_CR67","doi-asserted-by":"publisher","unstructured":"Clive\u00a0KS, et al.\u00a0The GP2 peptide: A HER2\/ neu \u2010based breast cancer vaccine. J Surg Oncol. 2012;105(5):452\u2013458.\u00a0https:\/\/doi.org\/10.1002\/jso.21723.","DOI":"10.1002\/jso.21723"},{"key":"3789_CR68","doi-asserted-by":"publisher","unstructured":"Chumsri\u00a0S, et al.\u00a0Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy. JCO. 2022;40(16_suppl):TPS610\u2013TPS610.\u00a0https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS610.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS610"},{"key":"3789_CR69","unstructured":"Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial. https:\/\/investor.greenwichlifesciences.com\/news-events\/press-releases\/detail\/96\/flamingo-01-phase-iii-clinical-trial."},{"key":"3789_CR70","doi-asserted-by":"publisher","unstructured":"Patel\u00a0S, et al.\u00a0Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01). J Clin Oncol. 2026;44(17_suppl).\u00a0https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA538.","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA538"},{"key":"3789_CR71","doi-asserted-by":"publisher","unstructured":"Sears\u00a0AK, et al.\u00a0AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011;11(11):1543\u20131550.\u00a0https:\/\/doi.org\/10.1517\/14712598.2011.616889.","DOI":"10.1517\/14712598.2011.616889"},{"key":"3789_CR72","doi-asserted-by":"publisher","unstructured":"Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods. 2003;278(1\u20132):79\u201393.\u00a0https:\/\/doi.org\/10.1016\/S0022-1759(03)00226-6.","DOI":"10.1016\/S0022-1759(03)00226-6"},{"key":"3789_CR73","doi-asserted-by":"publisher","unstructured":"Brown\u00a0TA, et al.\u00a0Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181(2):391\u2013401.\u00a0https:\/\/doi.org\/10.1007\/s10549-020-05638-x.","DOI":"10.1007\/s10549-020-05638-x"},{"key":"3789_CR74","doi-asserted-by":"publisher","unstructured":"Chumsri\u00a0S, et al.\u00a0Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy. JCO. 2024;42(16_suppl):550\u2013550.\u00a0https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.550.","DOI":"10.1200\/JCO.2024.42.16_suppl.550"},{"key":"3789_CR75","doi-asserted-by":"publisher","unstructured":"Ma Y, Zhu M, Lv M, Yuan P, Chen X, Liu Z. Impact of residual disease biomarkers on the prognosis of HER2 \u2010positive breast cancer following neoadjuvant therapy. Cancer Med. 2023;12(10):11293\u201311304.\u00a0https:\/\/doi.org\/10.1002\/cam4.5839.","DOI":"10.1002\/cam4.5839"},{"key":"3789_CR76","doi-asserted-by":"publisher","unstructured":"Geyer\u00a0CE, et al.\u00a0Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med. 2025;392(3):249\u2013257.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2406070.","DOI":"10.1056\/NEJMoa2406070"},{"key":"3789_CR77","doi-asserted-by":"publisher","unstructured":"Han\u00a0HS, et al.\u00a0A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2\u2013positive breast cancer. JCO. 2023;41(16_suppl):532\u2013532.\u00a0https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.532.","DOI":"10.1200\/JCO.2023.41.16_suppl.532"},{"key":"3789_CR78","doi-asserted-by":"publisher","unstructured":"Curigliano\u00a0G, et al.\u00a0Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol. 2006;17(5):750\u2013762.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdj083.","DOI":"10.1093\/annonc\/mdj083"},{"key":"3789_CR79","doi-asserted-by":"publisher","unstructured":"Dafni\u00a0U, et al.\u00a0Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. Eur Jnal of Cancer. 2021;142:63\u201382.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2020.10.014.","DOI":"10.1016\/j.ejca.2020.10.014"},{"key":"3789_CR80","doi-asserted-by":"publisher","unstructured":"Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA. Designing HER2 vaccines. Semin Oncol. 2002;29(3 Suppl 11):53\u201361.\u00a0https:\/\/doi.org\/10.1053\/sonc.2002.34056.","DOI":"10.1053\/sonc.2002.34056"},{"key":"3789_CR81","doi-asserted-by":"publisher","unstructured":"Curigliano\u00a0G, et al.\u00a0A phase I\/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;156(2):301\u2013310.\u00a0https:\/\/doi.org\/10.1007\/s10549-016-3750-y.","DOI":"10.1007\/s10549-016-3750-y"},{"key":"3789_CR82","doi-asserted-by":"publisher","unstructured":"Griguolo\u00a0G, et al.\u00a0Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ\u00a0Precis Onc.\u00a02021;5(1):23.\u00a0https:\/\/doi.org\/10.1038\/s41698-021-00163-6.","DOI":"10.1038\/s41698-021-00163-6"},{"key":"3789_CR83","doi-asserted-by":"publisher","unstructured":"Ramamoorthi\u00a0G, et al.\u00a0Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. J Immunother Cancer. 2022;10(6):e004841.\u00a0https:\/\/doi.org\/10.1136\/jitc-2022-004841.","DOI":"10.1136\/jitc-2022-004841"},{"key":"3789_CR84","doi-asserted-by":"publisher","unstructured":"Disis\u00a0ML, et al.\u00a0Concurrent Trastuzumab and HER2\/ neu -Specific Vaccination in Patients With Metastatic Breast Cancer. JCO. 2009;27(28):4685\u20134692.\u00a0https:\/\/doi.org\/10.1200\/JCO.2008.20.6789.","DOI":"10.1200\/JCO.2008.20.6789"},{"key":"3789_CR85","doi-asserted-by":"publisher","unstructured":"O\u2019Donovan N, Byrne AT, O\u2019Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR\/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs. 2011;29(5):752\u2013759.\u00a0https:\/\/doi.org\/10.1007\/s10637-010-9415-5.","DOI":"10.1007\/s10637-010-9415-5"},{"key":"3789_CR86","doi-asserted-by":"publisher","unstructured":"Hamilton\u00a0E, et al. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J Transl Med. 2012;10(1):28.\u00a0https:\/\/doi.org\/10.1186\/1479-5876-10-28.","DOI":"10.1186\/1479-5876-10-28"},{"key":"3789_CR87","doi-asserted-by":"publisher","unstructured":"Norell\u00a0H, et al.\u00a0Vaccination with a plasmid DNA encoding HER-2\/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 8(1):53.\u00a0https:\/\/doi.org\/10.1186\/1479-5876-8-53.","DOI":"10.1186\/1479-5876-8-53"},{"key":"3789_CR88","doi-asserted-by":"publisher","unstructured":"Disis MLN, et al.\u00a0Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2023;9(1):71.\u00a0https:\/\/doi.org\/10.1001\/jamaoncol.2022.5143.","DOI":"10.1001\/jamaoncol.2022.5143"},{"key":"3789_CR89","doi-asserted-by":"publisher","unstructured":"Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 \u2013Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2\u2013Overexpressing Breast Cancer. JCO. 2007;25(24):3680\u20133687.\u00a0https:\/\/doi.org\/10.1200\/JCO.2006.10.5718.","DOI":"10.1200\/JCO.2006.10.5718"},{"key":"3789_CR90","doi-asserted-by":"publisher","unstructured":"Chen\u00a0G, et al.\u00a0A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF\u2013Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunol Res. 2014;2(10):949\u2013961.\u00a0https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0058.","DOI":"10.1158\/2326-6066.CIR-14-0058"},{"key":"3789_CR91","doi-asserted-by":"publisher","unstructured":"Chen\u00a0S, et al.\u00a0Evaluation of clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis. eClinicalMedicine. 2025;86:103369.\u00a0https:\/\/doi.org\/10.1016\/j.eclinm.2025.103369.","DOI":"10.1016\/j.eclinm.2025.103369"},{"key":"3789_CR92","doi-asserted-by":"publisher","unstructured":"Hinshaw\u00a0DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557\u20134566.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962.","DOI":"10.1158\/0008-5472.CAN-18-3962"},{"key":"3789_CR93","doi-asserted-by":"publisher","unstructured":"Mittendorf\u00a0EA, et al.\u00a0Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735\u20131742.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdu211.","DOI":"10.1093\/annonc\/mdu211"},{"key":"3789_CR94","doi-asserted-by":"publisher","unstructured":"Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J Clin Invest.\u00a02001;107(4):477\u2013484.\u00a0https:\/\/doi.org\/10.1172\/JCI11752.","DOI":"10.1172\/JCI11752"},{"key":"3789_CR95","doi-asserted-by":"publisher","unstructured":"Maisonneuve C, Bertholet, Philpott DJ, De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111(34):12294\u201312299.\u00a0https:\/\/doi.org\/10.1073\/pnas.1400478111.","DOI":"10.1073\/pnas.1400478111"},{"key":"3789_CR96","doi-asserted-by":"publisher","unstructured":"Dubensky TW, Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Therapeut Adv Vaccines. 2013;1(4):131\u2013143.\u00a0https:\/\/doi.org\/10.1177\/2051013613501988.","DOI":"10.1177\/2051013613501988"},{"key":"3789_CR97","doi-asserted-by":"publisher","unstructured":"Gatti-Mays\u00a0ME, et al.\u00a0Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. Front Oncol.\u00a02021;10:581801.\u00a0https:\/\/doi.org\/10.3389\/fonc.2020.581801.","DOI":"10.3389\/fonc.2020.581801"},{"key":"3789_CR98","doi-asserted-by":"publisher","unstructured":"Wang X, Wang JP, Maughan MF, Lachman LB. Alphavirus replicon particles containing the gene for HER2\/neuinhibit breast cancer growth and tumorigenesis. Breast Cancer Res. 2004;7(1):R145.\u00a0https:\/\/doi.org\/10.1186\/bcr962.","DOI":"10.1186\/bcr962"},{"key":"3789_CR99","doi-asserted-by":"publisher","unstructured":"Bekaii-Saab\u00a0T, et al.\u00a0Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019;25(12):3495\u20133507.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3997.","DOI":"10.1158\/1078-0432.CCR-18-3997"},{"key":"3789_CR100","doi-asserted-by":"publisher","unstructured":"Liu G, et al.\u00a0Exosomal circRNAs: key modulators in breast cancer progression. Cell Death Discov.\u00a02025;11(1):196.\u00a0https:\/\/doi.org\/10.1038\/s41420-025-02494-w.","DOI":"10.1038\/s41420-025-02494-w"},{"key":"3789_CR101","doi-asserted-by":"publisher","unstructured":"Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, McArdle SEB. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Front Immunol.\u00a02021;11(615240).\u00a0https:\/\/doi.org\/10.3389\/fimmu.2020.615240.","DOI":"10.3389\/fimmu.2020.615240"},{"key":"3789_CR102","doi-asserted-by":"publisher","unstructured":"Holmes\u00a0JP, et al.\u00a0Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: From US Military Cancer Institute Clinical Trials Group Study I\u201001 and I\u201002. Cancer. 2011;117(3):463\u2013471.\u00a0https:\/\/doi.org\/10.1002\/cncr.25586.","DOI":"10.1002\/cncr.25586"},{"key":"3789_CR103","doi-asserted-by":"publisher","unstructured":"Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111\u2013118.\u00a0https:\/\/doi.org\/10.1586\/14760584.1.1.111.","DOI":"10.1586\/14760584.1.1.111"},{"key":"3789_CR104","doi-asserted-by":"publisher","unstructured":"Nimanong\u00a0S, et al.\u00a0CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. Cancer Res. 2017;77(8):1918\u20131926.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2089.","DOI":"10.1158\/0008-5472.CAN-16-2089"},{"key":"3789_CR105","doi-asserted-by":"publisher","unstructured":"Kim H, Kwon B, Sin JI. Combined Stimulation of IL-2 and 4\u20131BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses. PLoS ONE. 2013;8(12):e83765.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0083765.","DOI":"10.1371\/journal.pone.0083765"},{"key":"3789_CR106","doi-asserted-by":"publisher","unstructured":"Sikora\u00a0AG, et al.\u00a0IFN-\u03b1 Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity. J Immunol. 2009;182(12):7398\u20137407.\u00a0https:\/\/doi.org\/10.4049\/jimmunol.0802982.","DOI":"10.4049\/jimmunol.0802982"},{"key":"3789_CR107","doi-asserted-by":"publisher","unstructured":"Lee P, et al.\u00a0Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma. JCO. 2001;19(18):3836\u20133847.\u00a0https:\/\/doi.org\/10.1200\/JCO.2001.19.18.3836.","DOI":"10.1200\/JCO.2001.19.18.3836"},{"key":"3789_CR108","doi-asserted-by":"publisher","unstructured":"Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells. Cancer Res.\u00a02004;64(17):6337\u20136343.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0757.","DOI":"10.1158\/0008-5472.CAN-04-0757"},{"key":"3789_CR109","doi-asserted-by":"publisher","unstructured":"Kaczmarek\u00a0M, et al.\u00a0Cancer Vaccine Therapeutics: Limitations and Effectiveness\u2014A Literature Review. Cells. 2023;12(17):2159.\u00a0https:\/\/doi.org\/10.3390\/cells12172159.","DOI":"10.3390\/cells12172159"},{"key":"3789_CR110","doi-asserted-by":"publisher","unstructured":"Bottens RA, Yamada T. Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer. Cancers. 2022;14(22):5546.\u00a0https:\/\/doi.org\/10.3390\/cancers14225546.","DOI":"10.3390\/cancers14225546"},{"key":"3789_CR111","doi-asserted-by":"publisher","unstructured":"Moore J, Ali U, Vungarala S, Young\u2011Seigler A, Tiriveedhi V. Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer. Mol Clin Oncol. 2024;22(2):20.\u00a0https:\/\/doi.org\/10.3892\/mco.2024.2815.","DOI":"10.3892\/mco.2024.2815"},{"key":"3789_CR112","doi-asserted-by":"publisher","unstructured":"Liu\u00a0Y, et al.\u00a0Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis. Cell Commun Signal. 2025;23(1):333.\u00a0https:\/\/doi.org\/10.1186\/s12964-025-02321-w.","DOI":"10.1186\/s12964-025-02321-w"},{"key":"3789_CR113","doi-asserted-by":"publisher","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther. 2023;8(1):9.\u00a0https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","DOI":"10.1038\/s41392-022-01270-x"},{"key":"3789_CR114","doi-asserted-by":"publisher","unstructured":"Gupta RG, Li F, Roszik J, Liz\u00e9e G. Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discov. 2021;11(5):1024\u20131039.\u00a0https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1575.","DOI":"10.1158\/2159-8290.CD-20-1575"},{"key":"3789_CR115","doi-asserted-by":"publisher","unstructured":"Volpi\u00a0CC, et al.\u00a0The landscape of d16HER2 splice variant expression across HER2-positive cancers. Sci Rep. 9(1):3545.\u00a0https:\/\/doi.org\/10.1038\/s41598-019-40310-5.","DOI":"10.1038\/s41598-019-40310-5"},{"key":"3789_CR116","doi-asserted-by":"publisher","unstructured":"Crosby\u00a0EJ, et al.\u00a0Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \u03b1PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clin Cancer Res. 2020;26(17):4670\u20134681.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0389.","DOI":"10.1158\/1078-0432.CCR-20-0389"},{"key":"3789_CR117","doi-asserted-by":"publisher","unstructured":"Butterfield\u00a0LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416.\u00a0https:\/\/doi.org\/10.1038\/s41577-023-00973-8.","DOI":"10.1038\/s41577-023-00973-8"},{"key":"3789_CR118","doi-asserted-by":"publisher","unstructured":"Disis\u00a0ML, et al.\u00a0A Phase I\/II Trial of HER2 Vaccine\u2013Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2\u2013Overexpressing Breast Cancer. Clin Cancer Res. 2023;29(17):3362\u20133371.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3578.","DOI":"10.1158\/1078-0432.CCR-22-3578"},{"key":"3789_CR119","doi-asserted-by":"publisher","unstructured":"Wang S, Wang Y, Li Q, Li X, Feng X, Zeng K. The novel \u03b2-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer. Redox Biol. 2023;67:102896. https:\/\/doi.org\/10.1016\/j.redox.2023.102896.","DOI":"10.1016\/j.redox.2023.102896"},{"key":"3789_CR120","doi-asserted-by":"publisher","unstructured":"Admasu TD, Yu JS. Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy. Aging Cell. 2025;24(5):e70055. https:\/\/doi.org\/10.1111\/acel.70055.","DOI":"10.1111\/acel.70055"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03789-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:46:48Z","timestamp":1792723608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03789-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3789"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03789-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FP reportsresearch grants from AstraZeneca, Eisai, and Roche. FP has received consulting fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini, MSD, Novartis, Pfizer, and Roche; and payments\/honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, Italfarmaco, Menarini, MSD, Novartis, Pfizer, and Roche. FP has served in advisory roles for Amgen, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Novartis, Pfizer, and Roche. FP has received travel support and accommodation from AstraZeneca, Daiichi Sankyo, Menarini, Pfizer, and Roche, and has participated in advisory boards for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Menarini, MSD, Novartis, Pfizer, and Roche. LDM reports grants from Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, and MSD. LDM has received consulting fees from Novartis, Roche, Daiichi Sankyo, Eli Lilly, Gilead, Pfizer, Menarini Stemline, Olema, and AstraZeneca; and honoraria from Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, MSD, Exact Sciences, GSK, Ipsen, and Eisai. LDM has received travel grants from Roche, Gilead, Menarini Stemline, AstraZeneca, and Daiichi Sankyo. LDM has served on advisory boards for Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, MSD, Exact Sciences, GSK, Ipsen, and Eisai. LDM reports receipt of equipment from FoundationOne.MDL reports relationships with Roche, Novartis, Takeda, Eli Lilly, Pierre Fabre, AstraZeneca, MSD, Seagen, Gilead, Daiichi Sankyo, Tomalab, Genetic, Pfizer, Menarini, Sophos, Istituto Gentili, Sanofi, Ipsen, GSK, and Exact Sciences, including consulting\/advisory roles and travel reimbursement. MG reports relationships with AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Celgene, Exact Sciences, Eli Lilly, MSD, Novartis, Pfizer, Roche, and Seagen, including consulting\/advisory roles and travel reimbursement. GA reports relationships with Roche, Pfizer, Eli Lilly, MSD, AstraZeneca, and Novartis, including consulting\/advisory roles and research funding grants. CDA reports consulting or advisory relationships with Novartis, GSK, Eli Lilly, and Pfizer. All other authors declare no competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"220"}}